Inactive Instrument

Analyst Reco. Bio-Path Holdings Inc Nasdaq

Equities

HC Wainwright Adjusts Price Target on Bio-Path Holdings to $9 From $12, Reiterates Buy Rating	19/05/22	MT
BIO PATH : HC Wainwright Adjusts Price Target on Bio-Path Holdings to $12 From $10, Maintains Buy Rating	06/04/21	MT
BIO PATH : Roth Capital Starts Bio-Path Holdings at Buy With $13 Price Target	11/03/21	MT
BIO PATH : HC Wainwright Adjusts Bio-Path Holdings' Price Target to $10 from $12, Keeps Buy Rating	16/11/20	MT

No results for this search